- Home
- DT vs MDGL Comparison
DT vs MDGL Comparison
Compare DT & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DT | MDGL |
|---|---|---|
| Founded | 2005 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 12.8B |
| IPO Year | 2019 | 2005 |
Fundamental Metrics
Financial Performance| Metric | DT | MDGL |
|---|---|---|
| Price | $50.98 | $520.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 26 | 12 |
| Target Price | $51.77 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 6.4M | 366.6K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $2,018,387,000.00 | $180,133,000.00 |
| Revenue This Year | $21.74 | $58.39 |
| Revenue Next Year | $14.85 | $48.55 |
| P/E Ratio | $417.25 | ★ N/A |
| Revenue Growth | ★ 18.82 | N/A |
| 52 Week Low | $31.64 | $393.61 |
| 52 Week High | $53.29 | $615.00 |
Technical Indicators
Market Signals| Indicator | DT | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 62.03 | 46.08 |
| Support Level | $42.56 | $497.85 |
| Resistance Level | $52.64 | $545.13 |
| Average True Range (ATR) | 1.76 | 17.19 |
| MACD | -0.06 | -0.69 |
| Stochastic Oscillator | 67.69 | 29.60 |
Price Performance
Historical ComparisonAbout DT Dynatrace Inc.
Dynatrace is a software-as-a-service company that enables customers to monitor and analyze their information technology infrastructure, from servers to applications and Python scripts. Dynatrace's unified platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to optimize their business for service-level objectives and ensure uptime.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.